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Background: The aim of this study is to expand existing knowledge about the CRC-associated microbiome among
Han Chinese, and to further discover the variation pattern of the human CRC microbiome across all population.
Findings: Using pyrosequencing-based molecular monitoring of bacterial 16S rRNA gene from eight tumor/normal
tissue pairs of eight Chinese CRC patients, we analyzed and characterized the basic features of the CRC-associated
microbiome. Firstly, we discovered an increasing diversity among tumor-associated bacterial communities.
Secondly, in 50% of Chinese CRC patients, we found a significant increase of Roseburia (P = 0.017), and a concurrent
decrease of both Microbacterium (P = 0.009) and Anoxybacillus (P = 0.009) in tumor tissue.
Conclusions: We discovered a novel CRC microbiome pattern in Chinese. Both the over-represented Roseburia
bacteria at tumor sites and the over-represented Microbacterium and Anoxybacillus bacteria away from tumor sites
were both closely related in Chinese CRC patients. Across several populations reported in this study and previously,
we observed both common and distinctive patterns of human CRC microbiome’s association with a high-risk of
CRC.
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Bacterial infections play a potentially significant role in
the pathogenesis of colorectal cancer (CRC) [1-5],
though there are a variety of dietary, genetic, and envir-
onmental factors that add to CRC risk [6]. Previous
studies however have reported that various infectious
agents (e.g., Fusobacterium spp., Bacteroides fragilis, and
Escherichia coli) are related to a high-risk of CRC across
several different populations. These findings prompted
us ask whether such associations between CRC and
microbiome patterns are common or population-specific.
Such a finding to this question is essential in developing
personalized medicine strategies and treatment options
for CRC patients.
The aim of this study was to quantitatively evaluate
the differences of bacterial communities and composi-
tions between eight tumor/normal pairs from eight
Chinese CRC patients, as well as to characterize both* Correspondence: zhangzhigang@mail.kiz.ac.cn
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reproduction in any medium, provided the orthe common and various patterns of the human CRC
microbiome among different populations, ultimately to
contribute towards a preliminary understanding of the
bacterial driving forces at play in CRC.
Methods
Patients, sample collection, and DNA extraction
Eight Chinese CRC patients from Kunming, China were used
in this study with (56.9±14.4) (SD) average age, (22.97±1.56)
body mass index (BMI), and (1:1) male/female ratio. Four
patients were diagnosed as having rectal cancers while the
other half had colon cancers (ascending colon, transverse
colon, descending colon, and sigmoid). From the eight pa-
tients, we obtained a total 16 tissue samples, including
eight cancerous tissues and their matched adjacent normal
tissues obtained via colonoscopy following the Standard
Operating Procedures at the First People’s Hospital of
Yunnan Province of China, Kunming. Participants were
enrolled in the study prior to colonoscopy, and written in-
formed consent was obtained from the patient for publica-
tion of this report and any accompanying images. Samples
were removed endoscopically and immediately transferred
from the colonoscopy room to the pathology suite andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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one fragment of healthy tissue and one of tumor were
chosen and placed in a cryotube, then frozen immediately
in liquid nitrogen. All specimens were stored in their ori-
ginal tubes at -80°C prior to DNA extraction. This study
conformed to the ethical guidelines outlined in the 1975
Declaration of Helsinki as reflected by a priori approval
from the Medical Ethics Board of the First People's Hos-
pital of Yunnan Province of China.
While frozen, an aliquot (~25 mg) of each specimen
was suspended in a solution containing 200 ul buffer
ATL (QIAGEN Kit Buffer for tissue lysis) and 200 ul of
a slurry of 0.1-mm-diameter zirconia/silica beads
(BioSpec Products, Bartlesville, OK). The mixed sample
was then lysed by mechanical disruption with a bead
beater (BioSpec Products), set on high for 2 min (20°C),
followed by extraction with the QIAampW DNA Mini
Kit (Qiagen, Inc., Valencia CA). DNA from tissue was
eluted in a final volume of 200 ul elution buffer and
stored at -20°C. Tubes containing only QIAampW DNA
Mini Kit extraction controls were included throughout
lysis and PCR to serve as negative controls.PCR amplification of V1-V2 hypervariable regions of 16S
rRNA gene and pyrosequencing
The forward primer included the 454 Life Sciences pri-
mer B sequence (50 - CTATGCGCCTTGCCAGCCCG
CTCAG -30) and the broadly conserved bacterial primer
27 F (50-AGAGTTTGATCCTGGCTCAG-30). The re-
verse primer included the 454 Life Sciences primer A se-
quence (50-CGTATCGCCTCCCTCGCGCCATCAG- 30),
a unique 10-nt barcode used to tag each PCR product,
and the broad-range bacterial primer 338R (50- TGC
TGCCTCCCGTAGGAGT-30). Using the primer pair de-
scribed above, triplicate PCR reactions were performed
on each sample. Each resulting 25 ul reaction contained
0.2 μM forward and reverse primers, 3 μl template
DNA, and 2.5 ul 10X PCR buffer plus Mg2+ (TaKaRa),
2.0 ul dNTP (2.5 mM each) (TaKaRa), 0.75 ul DMSO
(100%), 0.25 ul TaKaRa Taq™ (5 U/μl). Thermal cycling
was conducted at 95°C for 10 minutes, followed by 30 -
cycles of 95°C for 30 seconds, 52°C for 30 seconds, and
72°C for 90 seconds, with a final extension of 10 minutes
at 72°C. Replicate amplicons were pooled and visualized
on 1.5% agarose gels using EB stain in 0.5X TE.
Amplicons were cleaned using MinEluteW Gel Extraction
Kit (Qiagen) according to the manufacturer’s instruc-
tions. Amplicon DNA concentrations were determined
using the Quant-iT PicoGreen dsDNA reagent and kit
(Invitrogen). Using the amplicon pool, we carried out
pyrosequencing using primer A and Titanium chemistry
on a 454 Life Sciences Genome Sequencer FLX instru-
ment (Roche) at the DNA Sequencing Facility of theKunming Institute of Zoology, Chinese Academy of
Sciences.
Bioinformatics analysis
Sequences were processed and analyzed using Qiime 1.4
[7]. Sequences were assigned to each sample by examin-
ing the 10-nt barcode based on the following criteria: a
minimum (min) sequence length of 200 nt; maximum
(max) sequence length of 400 nt; min qual score of 25;
maximum number of errors in barcode of 0; maximum
length of homopolymer run of 6; number of mismatches
in primer of 0; excluding ambiguous and unassigned
characters; and removed 454-adaptor B and 27 F bacter-
ial primer from all assigned sequence data. Sequencing
errors were removed from filtered sequences using
denoiser 0.91 [8]. Using Chimera Slayer [9], chimera se-
quences arising from the PCR amplification were
detected and excluded from the denoised sequences.
The chimera-free sequences were then clustered into op-
erational taxonomic units (OTUs) using CD-hit [10]
with a criterion of a minimum identity of 97%. Repre-
sentative sequences per OTU were classified using
BLAST with default parameters in Qiime 1.4. All OTUs
found in at least two samples were retained for
performing the following further analyses.
Statistical analysis
General characteristics were expressed as median and
mean or percentages. Comparisons were performed be-
tween tumor and normal samples using the Mann-
Whitney rank sum test or t-test in SigmaPlot 12.0
(Systat Software, Inc.). Statistical significance was set at
P < 0.05.
Results
We obtained a dataset consisting of 21,345 high-quality,
classifiable 16S rRNA gene sequences with an average of
1334.1 ± 521.9 (SD) (n = 16) sequences per sample, after
filtering raw data with our set of criteria (Methods).
From the dataset, we identified a total of 410 OTUs,
based on the conventional criterion of 97% sequence
similarity (equal to species level), with an average of
138.9 ± 46.2 OTUs per sample (n = 16). Compared with
normal results, the diversity index by both species rich-
ness (OTU number) and evenness (phylogeny-based
Chao1) suggested an increasing trend of microbial diver-
sity in tumors (mean; 122.3 ± 26.8 vs. 155.5 ± 56.8;
178.3 ± 41.0 vs. 230.7 ± 78.1). The significant difference
of bacterial diversity was further confirmed by distinctive
structural segregations of all 16 samples using PCoA
analysis based on phylogeny-based Unifrac matrix
(Figure 1).
By comparing the differences of bacteria components
between eight tumor/normal tissues from eight Chinese
Figure 1 16S rRNA gene surveys reveal hierarchical partitioning
of human tumor tissue-associated microbiomes. Bacterial
communities were clustered using Principal Coordinate Analysis
(PCoA) of the full-tree-based Unifrac matrix. Each point corresponds
to a sample colored to indicate tumor or healthy status. Three
principle components (PC1, PC2, and PC3) totally explained 43% of
the variation. Sample name started with their corresponding studied
patient number - S00X (X= 1, 2, 4, 5, 6, 7, 8, and 9), and the
following tissue type (C stands for cancer tissue and H for matched
adjacent health tissue).
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corresponding to each of three gut dominant bacteria
genera (Roseburia, Microbacterium, and Anoxybacillus)
(Figure 2A-2C), though each genus only showed one sig-
nificant increasing or decreasing pattern in tumor tissue.
Amongst 50% of patients, there was a significant in-
crease (P = 0.017) of Roseburia in tumor samples
(Figure 2A). Conversely, Microbacterium showed a signifi-
cantly (P = 0.009) lower abundance in tumor than in nor-
mal tissue (Figure 2B) in 75% of patients. Similarly, in 75%
of patients, Anoxybacillus also showed a significant de-
crease (P = 0.009) (Figure 2C) in tumors as compared with
the level found in normal tissue. Similarly, there was a
consistent underrepresentation of Microbacterium and
Anoxybacillus in tumors observed in 50% of patients.
Discussion
Our observations over the course of the study suggest
that we have discovered a novel pattern to the human
CRC microbiome among Han Chinese. According to the
bacterial driver-passenger model for CRC put forward
by Tjalsma et al (2012) [5], among 50% of Chinese CRC
patients in this study, the over-represented Roseburia
bacteria at tumor sites should in fact be considered as
‘passenger bacteria’ for CRC (previously known in other
populations, but not previously observed in Chinese) and
the over-represented Microbacterium and Anoxybacillusbacteria away from tumor sites—i.e., adjacent non-
malignant tissue—as ‘driver bacteria’ for CRC (novel
among all populations).
Consistent with several previous reports [3,4,11-13], we
also found an increasing trend of Fusobacterium spp. in
tumors among 87.5% of patients, though we did not dis-
cover a significant increase. Across several of the different,
previously studied populations including Europeans,
Americans, and Asians (in particular, Chinese and
Vietnamese), a similar pattern was observed; such a con-
sistent overrepresentation of Fusobacterium spp. in tumor
tissue suggests that there exists a common mechanism of
gut microbial disorder connected with CRC. This finding
implies that it is crucial to begin defining an underlying
association of the gut passenger bacteria Fusobacterium
with an increasing risk of CRC for most populations, des-
pite the lack of relative reports for many different popula-
tions to date.
We also found another gut bacterium, Roseburia, is
potentially associated with an increased risk of CRC, due
to the overrepresentation of Roseburia in tumor tissue
among Chinese, as we noted in this study, and as previ-
ously reported among Dutch [13]. This finding is con-
trary to the study done by Wang et al study on another
Chinese population [12] that compared the difference of
stool flora between CRC patients and healthy subjects.
Among the Chinese, the distinct discovery of Roseburia
and its potential association with CRC may be due to
different sample types, as another study done by Chen
et al indicated a different microbial structure between
the intestinal lumen and cancerous tissue in Chinese
CRC patients. The microbial structure difference be-
tween the intestinal lumen and mucosa tissue in healthy
subjects was further confirmed by Eckburg et al [14].
Additionally, two factors —diet and genetics—may have
minor effects on the differentiation of Roseburia for
CRC among Chinese, as we observed consistent overrep-
resentation of Roseburia in tumor tissues between the
Chinese and Dutch, two populations with higher divergence
of diet and genetics than within the Chinese population. Ac-
cordingly, the potential role of candidate gut passenger bac-
teria Roseburia should be emphasized more heavily during
the occurrence of CRC, regardless of the population (e.g.
Chinese or Dutch) and further investigated.
Similar to the relationship between CRC and gut bac-
teria Fusobacterium and Roseburia described above, the
‘passenger bacteria’ role of Bacteroides for CRC was sup-
ported by studies on the Chinese [12], Dutch [13], and
French [15]. And the ‘driver bacteria’ role of Bacteroides
was likewise confirmed by two other studies that exam-
ined a similar pattern among the Spanish, American and
Vietnamese [3,4]. Furthermore, Wu et al confirmed that
gut bacteria Bacteroides fragilis enables the promotion
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Figure 2 Statistical comparisons of three dominant gut bacteria genera between tumor and normal tissues. A-C respectively showed
two different variation patterns of each of three dominant bacteria genera (Roseburia, Microbacterium, and Anoxybacillus)–either the
overrepresentation in tumor sites or in normal sites (separated by slash). Those tumor/normal tissue pairs with significant differentiation of
dominant bacteria abundance were marked by a box. D, significantly increasing Roseburia in tumor tissue (mean, t-test) corresponding to four
tumor/normal pairs from 50% of patients marked by a box (A); E, significant decreasing Microbacterium in tumor (median, Mann-Whitney rank
sum test) corresponding to six tumor/normal pairs from 75% of patients marked by box (B); F, significant decreasing Anoxybacillus in tumor
(median, Mann-Whitney rank sum test) corresponding to six tumor/normal pairs from 75% of patients marked by a box (C). Sample names
started with their corresponding studied patient number - S00X (X= 1, 2, 4, 5, 6, 7, 8, and 9) and the following tissue type (C stands for cancer
tissue and H for matched adjacent health tissue).
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driving factor of colorectal cancer [2], and the ‘passenger
bacteria’ role of Escherichia species for CRC among the
Chinese was also implied by the study done by Wang
et al.. Moreover, besides the common pattern of the hu-
man CRC microbiome represented by gut passenger
bacteria Fusobacterium within and between populations,
there exists a diversified pattern in the human CRC
microbiome due to three possible factors. One may be
due largely to high variation of the normal human gut
microbiome [16], potentially associated with diet [17,18],
age [18,19], sample type (mucosa or stool) [14], host
genetic factors [20], or other factors, such as antibiotic
abuse [21]. Another factor may result from the different
stage of tumor progression that is randomly selected by
different studies, as the CRC microbiome variance may
be temporally associated with developing tumors [5].The last possible factor is that most findings to date
have only been derived from bacterial 16S rRNA-based
analyses, though some evidence from a metagenomic ap-
proach with a markedly more powerful ability to de-
cipher the landscape of human CRC microbiome are
intriguing [3,4]. Further studies of this kind will be help-
ful in confirming and elucidating the potential associa-
tions we have outlined in the present study.
In summary, in the present study we presented some
initial findings the lead towards a deeper and more com-
prehensive view of the human CRC microbiome. The
existing findings are suggestive of further research, and
underscore the necessity of borrowing from both high-
throughput meta-genomic or transcriptomic data and
(animal) model experiments that will better define and
validate the association of high-risk microbial populations
with occurrence of CRCs across different populations.
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